AB-101
As of the edition of 20 October 2026, AB-101 is a drug: in active development; acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Unknown
- Registered trials
- 7, 1 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Cancer; Blood and lymph; Urinary and reproductive; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of AB-101.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Applied Biology | Lead sponsor of trials | 2018 to now |
| Artiva Biotherapeutics | Lead sponsor of trials | 2021 to now |
| Arbutus Biopharma | Lead sponsor of trials | 2023 to now |
| Affimed | Lead sponsor of trials | 2023 to now |
| Iris | Lead sponsor of trials | 2024 to now |
| Alphyn Biologics | Lead sponsor of trials | 2025 to now |